Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Physiology profile

Dhananjie Chandrasekera

PositionPhD Student
DepartmentDepartment of Physiology
QualificationsMSc
Research summaryMicroRNA alterations in diabetic heart disease

Publications

Chamorro-Jorganes, A., Sweaad, W. K., Katare, R., Besnier, M., Anwar, M., Beazley-Long, N., … Chandrasekera, D., … Emanueli, C. (2021). METTL3 regulates angiogenesis by modulating let-7e-5p and miRNA-18a-5p expression in endothelial cells. Arteriosclerosis, Thrombosis, & Vascular Biology. Advance online publication. doi: 10.1161/atvbaha.121.316180

Purvis, N., Kumari, S., Chandrasekera, D., Bellae Papannarao, J., Gandhi, S., van Hout, I., Coffey, S., Bunton, R., Sugunesegran, R., Parry, D., Davis, P., Williams, M. J. A., Bahn, A., & Katare, R. (2021). Diabetes induces dysregulation of microRNAs associated with survival, proliferation and self-renewal in cardiac progenitor cells. Diabetologia. Advance online publication. doi: 10.1007/s00125-021-05405-7

Neale, J. P. H., Pearson, J. T., Thomas, K. N., Tsuchimochi, H., Hosoda, H., Kojima, M., … Jones, G. T., Denny, A. P., Daniels, L. J., Chandrasekera, D., Liu, P., van Rij, A. M., Katare, R., & Schwenke, D. O. (2020). Dysregulation of ghrelin in diabetes impairs the vascular reparative response to hindlimb ischemia in a mouse model; Clinical relevance to peripheral artery disease. Scientific Reports, 10, 13651. doi: 10.1038/s41598-020-70391-6

Chandrasekera, D. N. K., Neale, J. P. H., van Hout, I., Rawal, S., Coffey, S., Jones, G. T., … Manning, P., Williams, M. J. A., & Katare, R. (2020). Upregulation of microRNA-532 enhances cardiomyocyte apoptosis in the diabetic heart. Apoptosis, 25(5-6), 388-399. doi: 10.1007/s10495-020-01609-1

Bittar, T. P., Nair, B. B., Kim, J. S., Chandrasekera, D., Sherrington, A., & Iremonger, K. J. (2019). Corticosterone mediated functional and structural plasticity in corticotropin-releasing hormone neurons. Neuropharmacology, 154, 79-86. doi: 10.1016/j.neuropharm.2019.02.017